Logo
Logo


ISSN: 0300-9041
ISSNe: 2594-2034


Indizada en: SciELO, Índice Médico Latinoamericano, LILACS, Medline
Editada por la Federación Mexicana de Colegios de Obstetricia, y Ginecologia AC
Fundada por la Asociación Mexicana de Ginecología y Obstetricia en 1945
 

INFORMACIÓN EXCLUSIVA PARA LOS PROFESIONALES DE LA SALUD


Periodicidad: continua
Abreviatura: Ginecol Obstet Mex
ISSN: 0300-9041
ISSNe: 2594-2034
Indizada en: Scimago, Índice Médico Latinoamericano, Lilacs, Medline, Science Citation Index, Ulrich, Ebsco.

Utilidad de un esquema combinado de FSH + LH recombinantes versus FSH recombinante sola en ciclos de fertilización in vitro

Recombinant FSH versus recombinant FSH + LH during GnRH antagonist ovarian stimulation for in vitro fertilization.

Ginecol Obstet Mex. 2017 noviembre;85(11):727-734.

https://doi.org/10.24245/gom.v85i10.1187

Kably-Ambe A,1 Carballo-Mondragón E,2 Durán-Monterrosas L,3 Roque-Sánchez AM4

1 Director.
2 Directora del laboratorio.
3 Adscrita al laboratorio.
4 Coordinador clínico.
Centro Mexicano de Fertilidad CEPAM, Hospital Ángeles Lomas, Huixquilucan, Estado de México.


Corrrespondencia:

Dr. Alberto Kably Ambe
cepam1999@gmail.com

Debe citarse como:

Kably-Ambe A, Carballo-Mondragón E, Durán-Monterrosas L, Roque-Sánchez AM. Utilidad de un esquema combinado de FSH + LH recombinantes versus FSH recombinante sola en ciclos de fertilización in vitro. Ginecol Obstet Mex. 2017 nov;85(11):727-734. DOI: https://doi.org/10.24245/gom.v85i10.1187

Resumen

OBJETIVO: comparar el efecto de añadir LH recombinante a ciclos de estimulación para reproducción asistida versus ciclos solo estimulados con FSH recombinante (FSHr).

MATERIALES Y MÉTODOS: estudio retrospectivo, comparativo, observacional y transversal de ciclos de fertilización in vitro efectuados en el Centro Mexicano de Fertilidad del CEPAM divididos en dos grupos, según el tipo de gonadotropina administrada.

RESULTADOS: se estudiaron 529 ciclos en los que el desarrollo folicular y la cantidad de ovocitos fueron mayores en el grupo estimulado solo con FSHr. Sin embargo, el porcentaje de ovocitos en metafase II fue mayor en el grupo con LHr. La tasa de embarazo fue mayor en el grupo estimulado con LHr.

CONCLUSION: la ventaja de añadir LHr a ciclos de estimulación en reproducción asistida se refleja en mayores tasas de embarazo.

PALABRAS CLAVE: fertilización in vitro, LH recombinante, tasa de embarazo.

Abstract

OBJECTIVE: To evaluate the effect of adding recombinant LH to IVF GnRH cycles compared to recombinant FSH stimulated cycles.

MATERIALS AND METHODS: A retrospective, observational, cross-sectional study of 486 cycles of in vitro fertilization was done in the Centro Mexicano de Fertilidad of CEPAM (Hospital Angeles Lomas). We included 529 cases where it was used a stimulation protocol GnRH antagonist flexible scheme and analyzed depending on the utilized gonadotropin scheme.

RESULTS: 529 cycles were studied in which the follicular development and the number of oocytes were higher in the group stimulated with FSHr alone. However, the percentage of oocytes in metaphase II was higher in the group with LHr. The pregnancy rate was higher in the group stimulated with LHr.

CONCLUSION: There is a benefit of adding rLH to IVF GnRH antagonist stimulation protocols resulting in higher pregnancy rates.

KEYWORDS: In vitro fertilization; recombinant LH; pregnancy rate

    1. Hill M, Levens E, Levy G, Ryan M, Csokmay J, DeCherney A, Whitcomb B. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril 2012;97:1108-14.
    2. Huddleston H, Jackson K, Doyle J. Racowsky C. hMG increases the yield of mature oocytes and excellent-quality embryos in patients with a previos cycle having a high incidence of oocyte immaturity. Fertil Steril 2009;92:946-9.
    3. Requena et al. Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin. Reproductive Biology and Endocrinology 2014 12:10.
    4. Filicori M. Use o luteinizing hormone in the treatment of infertility: time for reassesment? Fertil Steril 2003; 79:253-5.
    5. Marrs R. Meldrum D, Muasher S. Schoolcraft W, Werlin L, Keely E. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or withou recombinant human LH in women undergoing assisted reproduction treatment. 2003;8:175-82.
    6. Nyvoe A, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombination FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Human Reproduction 2006; 21:3217-27.
    7. Faremi H.M, Blockeel C, Devroey P. Ovarian Stimulation: Today and Tomorrow. Curr Pharma Bio, 2012;13:1-6.
    8. Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril 2010; 94:1467-69.
    9. Fisher R. Understanding the role of LH: myths and facts. Reprod Biomed 2007;15:468-77.
    10. Kovacs P, Kovats T, Kaali S. Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. 2010 Fertil Steril 93;2:475-79.
    11. Agostineto R. Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment. Reprod Biomed Online 2009 7:48-52.

Comentarios